2022 Annual Psychiatric Update

Information

2020 Annual Psych Update Graphic Adobe Stock 390381701

Hot Topics in Psychiatry:

Advancing Clinical Care While
Surviving the Pandemic’s Impact


Virtual on April 2, 2022

 

 

The pandemic has heightened the awareness of both physical and mental/behavioral concerns in all populations in the state of Ohio. It has been nearly two years since COVID-19 created the challenges that our patients face, including illness, loss of employment, financial problems, lack of food, closed schools and loss of life. It has all taken a tremendous toll on our patients from a social, emotional and vocational perspective and the effects will be long-standing. At the same time, the field of psychiatry continues to see advances in the field. This educational activity will address both pandemic-related mental health issues and new advances in the treatment of psychiatric disorders.

WHO SHOULD ATTEND

This program is designed specifically for Psychiatrists, Residents, Medical Students and other Physicians, including Primary Care and Pediatricians, as well as Psychologists, Nurses, Social Workers, Counselors and other Mental Health Care Professionals.

CONTINUING EDUCATION PHYSICIANS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Psychiatric Association (APA) and the Ohio Psychiatric Physicians Association (OPPA). The APA is accredited by the ACCME to provide continuing medical education for physicians.

The American Psychiatric Association designates this live activity, Hot Topics in Psychiatry: Advancing Clinical Care While Surviving the Pandemic’s Impact for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EVALUATION
This educational activity will be evaluated utilizing an online evaluation form to evaluate the effectiveness of the CME activity in meeting the identified educational needs and stated learning objectives in terms of satisfaction, knowledge, skills and any perceived commercial bias. At the conclusion of this educational event, you will be provided with a link to the evaluation form. After completing the evaluation you will be provided with an opportunity to print a certificate for continuing education credit.

PLANNING COMMITTEE DISCLOSURE

It is the policy of the APA to comply with the ACCME Standards for Commercial Support of CME. Planning committee members and related staff disclosures are on file and disclosed on program materials. Faculty participating in sponsored or jointly provided meetings of the APA are required to disclose to program participants any financial relationships with commercial interests that they (or their spouse/partner) have related to the content of their presentations. Faculty disclosures are identified as a faculty cover sheet with their respective syllabus/handout materials. Faculty are also responsible for disclosing any discussion of off-label or investigational use of a product.

The following individuals of the planning committee have indicated neither they, nor their spouse/partner, have any financial relationship with any commercial source: Brian Evans, DO, Rebecca Ekstrand, MD, Karen Jacobs, DO, Victoria Kelly, MD, Selena Magalotti, MD, Suzanne Sampang, MD, Janet Shaw, MBA, Heather Theibert, DO, and Kristi Williams, MD.

 

Click  HERE to view complete brochure

 

 

Speakers

Photo Altinay Murad Md Cropped

Murat Altinay, MD, is an adult psychiatrist with interests in treatment resistant mood disorders (major depressive disorder and bipolar disorder), neuromodulation (transcranial magnetic stimulation (TMS), deep brain stimulation (DBS)) and LGBT mental health. He is currently the principal investigator of several clinical trials including the “Electroconvulsive Therapy (ECT) vs. Ketamine in Patients with Treatment Resistant Depression (TRD) (ELEKT-D) study”, “Transcranial Magnetic Stimulation in Smokers: an Examination of Mediating Neural Pathways”, “Modulation of anterior cingulate and dorsolateral prefrontal cortex GABA and functional connectivity following repetitive transcranial magnetic stimulation therapy in major depressive disorder”,  and “Registry: Patients Having Repeated Intravenous Ketamine Infusions for the Treatment of Highly Treatment-Resistant Depression”. He is also a co-investigator of “Ketamine Treatment of Youth Suicide Attempters for Fast Reduction of Severe Suicide Risk and Facilitation of Long-term Collaborative Clinical Engagement: A Double Blind Randomized Placebo Controlled Trial” and “Transgender Women’s Perspectives on Mental Health Care Related to Gender Affirmation Surgery”.

Photo John Barry 7 Cropped Small From Web

John M. Barry is a prize winning historian whose work has involved him in public policy. The National Academies of Sciences named his 2004 book The Great Influenza, a #1 New York Times best-seller, the year's best book on science or medicine. A member of the original team to recommend non-pharmaceutical interventions to mitigate a pandemic, he advised both the Bush and Obama White House on pandemic response, and he also worked with United Nations, state, local, and private sector entities on resilience issues. A member of advisory boards at MIT and Johns Hopkins, he is Distinguished Scholar at the Tulane University School of Public Health and Tropical Medicine.

Photo David Putrino Cropped

David Putrino, PT, PhD, is a physical therapist with a PhD in Neuroscience. He studied computational neuroscience at Harvard Medical School, MIT and NYU. He is currently the Director of Rehabilitation Innovation for the Mount Sinai Health System, and an Associate Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mount Sinai. He develops innovative rehabilitation solutions for adults and children in need of better healthcare accessibility. He also works with high performance partners such as Red Bull, the Brooklyn Nets NBA team and the US Olympic team to use evidence-based technologies to improve athletic performance. He is the author of Hacking Health: How to make money and save lives in the HealthTech world. In 2019, he was named "Global Australian of the Year" for his contributions to healthcare.

Photo Sloshower Cropped

Jordan Sloshower, MD, MSc, is a psychiatrist, researcher, and educator whose work focuses on therapeutic applications of psychedelic medicines, and in particular, how these novel treatments can be integrated with psychotherapy and other healing modalities to promote holistic healing. He is currently a faculty member in the Yale Department of Psychiatry, where he co-founded the Yale Psychedelic Science Group and serves as an investigator and therapist in several clinical trials of psilocybin-assisted therapy. Jordan is also a clinical investigator in MAPS’ Expanded Access Program for MDMA-assisted therapy of PTSD and serves as a lead trainer with Usona Institute’s psilocybin facilitator training program. Most recently, he was elected to the Board of Directors of the American Psychedelic Practitioners Association, reflecting his commitment to ethical stewardship of psychedelic medicines.

Agenda


7:30 – 8:45 a.m. Annual Business Meetings: OPPA, OPPAC, OPPF
7:30 - 8:30 a.m. Medical Student Meeting (break-out room)
7:30 a.m. – 3:30 p.m. Video Poster Presentations (break-out room until 3:30 pm)
8:30 – 9 a.m. Break/Visit Exhibitors
9 – 10 a.m.

Neuromodulation and Other Novel Treatment in Mood Disorders

Murat Altinay, MD, Cleveland Clinic Foundation

Major Depressive Disorder (MDD) is one of the most prevalent psychiatric illnesses. Patients who fail to respond to at least two medication trials are diagnosed with "treatment resistant depression" (TRD). Current antidepressants and the monoamine hypothesis fail to help with depressive symptoms in the TRD population. It is therefore of great importance to look at other mechanisms that play a role in pathophysiology of depression. In this talk we will focus on: 1)the glutamate system as one of the mechanisms of depression, 2) review over the counter supplements and augmentation agents that have antidepressant effects, 3) talk about neuromodulation therapies (with emphasis on TMS, ECT, VNS, Eand DBS) and other new treatment modalities (ketamine and psychedelics) and 4) some of the current and future research directions in the field.

10 – 10:30 a.m.  

Break/Visit Exhibitors

10:30 – 11:30 a.m.  

The Henry and Amelia Nasrallah Annual OPPA Lectureship on Advances in Psychiatry

Psilocybin-Assisted Therapy for Major Depressive Disorder     

Jordon Sloshower, MD, MSc, Yale University

Preliminary evidence suggests that psychedelic treatments have therapeutic potential across a range of mental disorders and psilocybin-assisted therapy was recently granted breakthrough status by the FDA as a treatment for Major Depressive Disorder (MDD). In this talk, Dr Jordan Sloshower will present the design and results of his study of psilocybin-assisted therapy for MDD. This research investigates potential neurobiological and psychological mechanisms of action, namely induction of neuroplasticity and psychological flexibility. He will also discuss how this study uniquely employed Acceptance and Commitment Therapy (ACT) as an overarching psychotherapeutic framework. The talk will conclude with reflections on methodological and ethical challenges facing the field of psychedelic medicine.

11:30 a.m. – Noon 

Break/Visit Exhibitors

Noon – 1 p.m.  

Facilitated Breakout Discussions

The topics addressed during this year’s meeting can impact certain subpopulations in different ways. After participating in the morning sessions with clinical experts, participants will be separated into one of the six breakout groups (self-selected during registration) to discuss how the pandemic and clinical innovations impact different subpopulations and identify factors that must be considered for each population. The subpopulations include: Children and Adolescents, Geriatrics, Substance Use Disorders, LGBTQ+, Women, and Racial/Ethnic Minorities. A facilitator for each group will guide discussions during the breakout sessions. At the conclusion of the breakout discussions, each group will share a summary of their small group discussion with the larger group.  

1 – 1:30 p.m.  

Break/Visit Exhibitors

1:30 – 2:30 p.m. 

A Medical Historian's Perspective on Pandemics 

John Barry, Distinguished Scholar, Tulane University School of Public Health and Tropical Medicine

Can and should Medical History inform how we manage current and future pandemics? While there are certainly differences between the 1918-1919 Influenza outbreak and COVID 19, there are many lessons to be learned. Immediate actions of non – pharmaceutical interventions proved to “flatten the curve” and reduce mortality. Then, as now, there was push back regarding how to implement effective interventions sustainably. Edwin Chadwick, a reformer and early leader in public health, first called attention to the fact that “the poor don’t get sick because they’re bad or unworthy, they get sick because they’re poor, living in crowded conditions, without access to health care.”  We hope to learn how to embrace an approach that addresses such systemic issues.

2:30 – 3 p.m.

Break/Visit Exhibitors

3 – 4 p.m.

COVID Long Haulers

David Putrino, PT, PhD, Ican School of Medicine at Mount Sinai

Long COVID is a highly debilitating set of conditions that is affecting millions of people who were initially infected with acute SARS-CoV2 Virus. Long COVID affects nearly every organ system and causes significant physical, social, emotional and psychological consequences. This presentation will aim to provide insight into some emerging holistic and person-centered approaches to long COVID management. Potential pathophysiology of long COVID, current assessment and interventional approaches, as well as avenues for future research and investigation will be discussed. 

4 – 4:15 p.m. 

Final Comments

 

Announce Poster Presentations 1st and 2nd Place Submissions

4:15 – 5 p.m. 

Medical Student After Meeting

    

Register

REGISTRATION
The preferred method of registration is online. Click HERE. Be sure to register before March 1 to receive the best rate.

  Early-bird rate (prior to Mar. 1) Regular rate
OPPA Member: $75 $115
OPPA Resident-Fellow Member: $25 $55
     

Non-Member Psychiatrist, other Physician, or Psychologist, Nurse, Counselor, Social Worker or Physician Assistant

$225 $250

Non-Member Resident-Fellow

$75 $115

 

If you prefer to register by mail, please complete the registration form and send with payment to: Ohio Psychiatric Physicians Association, 3510 Snouffer Rd., Ste. 101, Columbus, OH 43235-4217. Make check payable to Ohio Psychiatric Physicians Association. Your registration is not confirmed until payment is received.

MEDICAL STUDENTS
As in years past we hope to provide sponsorships to cover the cost of registration for medical students to attend. However, if you would like to secure your space now you may register below for only $25. If you want to be added to a list for possible sponsorship or are ready to register and pay the $25 registration fee, click HERE to register. Students will be notified by Mar. 14, 2022 if there is a sponsorship available. Priority will be given to students who have not attended in the past. There will be specific time for medical students to meet with other Ohio medical students and to learn from residents and others about psychiatry residency and career opportunities.

Cancellation Policy:
If you are not able to attend, we encourage you to send someone in your place. Refund of the registration fee, minus a $50 administrative charge will be allowed if request for cancellation is received in writing by Mar. 5, 2022. After this date no refund will be made.

 

Supporters and Exhibitors

The Ohio Psychiatric Physicians Association is once again inviting outside companies, that have a product or service that is of interest to psychiatric physicians, to participate in its 2022 virtual Annual Psychiatric Update on Saturday, April 2, 2022.

This is a great opportunity for company representatives to interact with and/or make your products and services known to hundreds of psychiatrists (including some of Ohio's most prominent psychiatric physician leaders),  advanced practice registered nurses and other behavioral health providers.

As always, OPPA will work to maximize success for exhibitors and supporters by offering increased opportunities for attendee interaction. New this year is an opportunity to conduct a 25-minute product theater, outside of the educational event, during one of the four 30-minute breaks.

 

 

 

 

 

 

 

 

Exhibitor Prospectus Psychiatric Update 2022 Exhibitor Prospectus Front CoverSign-Up Here

 

 

 

 

 

 

 

 

 

 

 


PLATINUM SUPPORTER

Logo - PRMS

EXHIBITORS

American Professional
Agency, Inc.

Jannsen

Northwestern Mutual Wealth Management Company

Ohio Physicians Health Program

Otsuka

The Emily Program

 

 

 

 

 

 

 

The Ohio Psychiatric Physicians Association is once again